

# The PD-L1 metabolic interactome intersects with choline metabolism and inflammation

**Jesús Pacheco-Torres**

Johns Hopkins University School of Medicine <https://orcid.org/0000-0001-7070-7042>

**Marie-France Penet**

Johns Hopkins University School of Medicine

**Yelena Mironchik**

Johns Hopkins School of Medicine

**Balaji Krishnamachary**

Johns Hopkins School of Medicine

**Zaver M Bhujwala** (✉ [zbhujwa1@jhmi.edu](mailto:zbhujwa1@jhmi.edu))

<https://orcid.org/0000-0002-6617-9360>

---

## Research

**Keywords:** Immune checkpoints, PD-L1, choline kinase alpha, COX-2, breast cancer.

**DOI:** <https://doi.org/10.21203/rs.3.rs-103116/v2>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

**Background:** Harnessing the power of the immune system by using immune checkpoint inhibitors has resulted in some of the most exciting advances in cancer treatment. The full potential of this approach has, however, not been fully realized for treating many cancers such as pancreatic and breast cancer. Cancer metabolism influences many aspects of cancer progression including immune surveillance. An expanded understanding of how cancer metabolism can directly impact immune checkpoints may allow further optimization of immunotherapy. We therefore investigated, for the first time, the relationship between the overexpression of choline kinase- $\alpha$  (Chk- $\alpha$ ), an enzyme observed in most cancers, and expression of the immune checkpoint PD-L1.

**Methods:** We used small interfering RNA to downregulate Chk- $\alpha$ , PD-L1 or both in two triple negative human breast cancer cell lines (MDA-MB-231 and SUM-149) and two human pancreatic ductal adenocarcinoma cell lines (Pa09C and Pa20C). The effects of the downregulation were studied at the genomic, proteomic and metabolomic levels. The findings were compared with results obtained by analysis of public data from The Cancer Genome Atlas Program.

**Results:** We identified an inverse dependence between Chk- $\alpha$  and PD-L1 at the genomic, proteomic and metabolomic levels. We also found that prostaglandin-endoperoxide synthase 2 (COX-2) and transforming growth factor beta (TGF- $\beta$ ) play an important role in this relationship. We independently confirmed this relationship in human cancers by analyzing data from The Cancer Genome Atlas Program.

**Conclusions:** Our data identified previously unknown roles of PD-L1 in cancer cell metabolic reprogramming, and revealed the immunosuppressive increased PD-L1 effect of Chk- $\alpha$  downregulation. These data suggest that PD-L1 regulation of metabolism may be mediated through Chk- $\alpha$ , COX-2 and TGF- $\beta$ . The observations provide new insights that can be applied to the rational design of combinatorial therapies targeting immune checkpoints and cancer metabolism.

## Background

The cancer immunotherapy field has been revitalized with the discovery of immune checkpoints such as programmed cell death protein-1 (PD-1), and its ligand (PD-L1, *CD274*), that act as natural regulators of the immune system (1). Along with the expanded interest in blocking immune checkpoints for cancer immunotherapy, recent studies have also identified the important role of metabolism in immune suppression and the tumor immune microenvironment (TIME) (2, 3). Cancer cells can create an immune suppressive microenvironment through metabolic reprogramming, by changing the metabolic profile of the tumor microenvironment (TME) and exerting high metabolic stress on tumor infiltrating immune cells that lead to their functional inactivation (4-7). High glycolysis and lactate production (8, 9), glutamine deprivation (10) and changes in the redox state (11) have been shown to influence the TIME. PD-L1 levels are, furthermore, directly modulated in cancer cells by lactate (12), arginine (13) or glutamate (14),

and in immune cells by arginine (13) and glutamine (15). As a result, metabolic inhibitors of glutamate, glutamine and arginine pathways are being evaluated in clinical trials in combination with immune-checkpoint inhibitors with promising outcomes (6).

Most cancers exhibit an aberrant choline metabolism that is characterized by increased phosphocholine (PC) and total choline-containing compounds (16, 17). These changes have been attributed, in large part, to the overexpression and increased activity of choline kinase (Chk)-a, encoded by *CHKA*, in malignant cells (18, 19). Chk-a catalyzes the phosphorylation of choline (Cho) to PC, a major component of phosphatidylcholine (PtdCho) cycle. PtdCho is the most abundant phospholipid of the eukaryotic cell membrane, and an important source of signaling molecules (20). The prognostic and oncogenic roles of Chk-a have been described in studies with different tumor types (21-23), relating Chk-a overexpression to tumor progression, metastasis, and the activation of oncogenic signaling pathways (24). As a result, Chk-a inhibitors are being evaluated as therapeutic agents (25, 26), with at least one that has recently completed a phase I clinical trial (27). Despite being one of the most consistently altered metabolic pathway in cancers, the relationship between choline metabolism and immune checkpoints has, to date, not been investigated. New insights into the interaction between choline metabolism and immune checkpoints may lead to improved treatment outcomes.

Here, for the first time, we investigated the relationship between choline metabolism and the immune checkpoint PD-L1, in human triple negative breast cancer (TNBC) and pancreatic ductal adenocarcinoma (PDAC) cells. We focused on TNBC and PDAC because the outcomes of immune checkpoint inhibitor treatments in these cancers have yet to match the successes observed in melanoma and lung cancer (28, 29). PDAC, especially, has poor survival rates (30). Chk-a and PD-L1 were downregulated using Chk-a and PD-L1 specific small interfering RNA (siRNA). The functional impact of Chk-a and PD-L1 downregulation on the PD-L1 metabolic interactome was characterized by performing high-resolution <sup>1</sup>H magnetic resonance spectroscopy (MRS) of cell extracts to quantify changes in metabolic patterns. We found an inverse dependence between Chk-a and PD-L1 levels in three of the four cancer cell lines investigated that was mediated, in part, by prostaglandin-endoperoxide synthase 2 (COX-2) and transforming growth factor beta (TGF-β). The multiple metabolic changes observed when Chk-a and PD-L1 were downregulated individually were largely attenuated when both were downregulated together, further supporting the important role of Chk-a in the PD-L1 metabolic interactome and *vice versa*. These results were independently verified in human cancers by analysis of data from The Cancer Genome Atlas Program (TCGA) that confirmed a significant negative correlation between Chk-a and PD-L1 expression.

## Methods

### Cell lines

Triple negative MDA-MB-231 human breast cancer cells (ATCC Cat# HTB-26, RRID: CVCL\_0062, female) were obtained from ATCC (Manassas, VA, USA). MDA-MB-231 cells with COX-2 silenced (shCOX2-MDA-MB-231) were created through the use of a short hairpin RNA-coding plasmid constructed and placed

under the control of the U6 promoter as previously described (31). Triple negative SUM-149 human breast cancer cells (CVCL\_3422, RRID: CVCL\_3422, female) were obtained from Asterand (Asterand Inc., Detroit, MI, USA). Pa09C (Panc215, RRID: CVCL\_E286, female) and Pa20C (Panc198/RRID: CVCL\_E285, male) human pancreatic cancer cells obtained from primary PDAC were kindly provided by Dr. Anirban Maitra (32). All cell lines were authenticated within the past 6 months at the Johns Hopkins Genetic Resource Core Facility that follows ASN-0002-2011, Authentication of Human Cell Lines: Standardization of STR Profiling guidelines. The STR profiles of MDA-MB-231 AND shCOX2-MDA-MB-231 cells were verified using the ATCC database, and the STR profile of SUM-149 cells was verified using the ExPASY Bioinformatics Resource Portal in the Cellosaurus database (33). STR profiling of the pancreatic cancer cell lines confirmed absence of cross-contamination. All the cell lines used in this study tested negative for mycoplasma within the past six months.

## **Cell culture**

Cells were cultured under standard cell culture incubator conditions at 37 °C in a humidified atmosphere containing 5% CO<sub>2</sub> and were used from passages 3-7. MDA-MB-231 cells were maintained in RPMI 1640 medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich,). shCOX2-MDA-MB-231 cells were maintained in RPMI 1640 medium supplemented with 10% FBS and G418 sulfate (Corning, Corning, NY, USA) at a concentration of 400 µg/ml. SUM-149 cells were maintained in DMEM/Ham's F12 50/50 medium (Sigma-Aldrich) with 5% calf serum, insulin (5 µg/ml), and hydrocortisone (1 µg/ml). Pa09C cells were cultured in RPMI-1640 with 20% FBS, 12.5 mmol/L glucose, and 2 mmol/L glutamine. Pa20C cells were cultured in DMEM (Sigma-Aldrich) with 10% FBS, 25 mmol/L glucose, and 4 mmol/L glutamine.

## **RNA interference experiments**

All siRNA were purchased from Dharmacon (Lafayette, CO, USA). Untreated cells and cells treated with non-targeted scrambled siRNA (Dharmacon, Catalog Item D-001810-10-20) or luciferase siRNA (Dharmacon, Catalog Item P-002099-01-50) were used as controls. Isoform-specific siRNAs were custom designed using Thermo Scientific siRNA Design Center (Thermo Scientific, Rockford, IL, USA). siRNA specific sequences were 5'-CAUGCUGUCCAGUGCUC-3' for Chk-α, 5'-GAGGAAGACCUGAAGGUUCAGCAUA-3' for PD-L1 #1 and 5'-CCUACUGGCAUUUGCUGAACGCAUU-3' for PD-L1 #2.

Cells at 40% to 50% confluency were transfected with 100 nM of scrambled or luciferase siRNA, and with 50nM or 100 nM of Chk-α or PD-L1 specific siRNA for individual treatments. For combination siRNA treatments, 50 nM of each specific siRNA was used. Cells were treated with siRNA for 48 h because this incubation period resulted in the most effective downregulation of the target genes. D-FECT 4 (Dharmacon, Catalog Item T-2004-03) was used as the transfection agent for MDA-MB-231, Pa09C and Pa20C cells and Lipofectamine 2000 (ThermoFisher, Waltham, MA, USA, Catalog Item 11668019) for SUM-149 cells. All transfections were carried out based on established protocols (34).

## RNA isolation, cDNA synthesis, and RT-PCR

Approximately  $0.4 \times 10^6$  cells were incubated with different siRNA as previously described (34). Total RNA was isolated from cells using the QIAshredder and RNeasy Mini kit (Qiagen, Valencia, CA, USA) as per the manufacturer's protocol. cDNA was prepared using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). Real-time PCR of cDNA samples was performed using IQ SYBR Green supermix and gene specific primers in the iCycler real-time PCR detection system (Bio-Rad). All primers were designed using either Beacon designer software 7.8 (Premier Biosoft, Palo Alto, CA, USA) or publicly available Primer3plus software. The expression of target RNA relative to the housekeeping gene hypoxanthine phosphoribosyltransferase 1 (HPRT1) was calculated based on the threshold cycle ( $C_t$ ) as  $R = 2^{-\Delta(\Delta C_t)}$ , where  $\Delta C_t = C_t$  of target gene -  $C_t$  of HPRT1 and  $D(\Delta C_t) = \Delta C_t$  siRNA treated cells -  $\Delta C_t$  untreated cells .

## Protein isolation and immunoblots

Approximately  $10^6$  cells were incubated with different siRNA for 24h, 48h and 72h. Total protein was extracted using a 1x cracking buffer [100 mmol/L Tris (pH 6.7), 2% glycerol] containing a protease inhibitor (Sigma) at 1:200 dilution. Protein concentration was estimated using the Bradford Bio-Rad protein assay Kit (Bio-Rad). Approximately 100  $\mu$ g of total protein was used in each experiment.

Expression levels of Chk-a, PD-L1 and COX-2 were determined by immunoblotting using a custom-made polyclonal antibody against Chk-a at 1:200 dilution, a rabbit polyclonal against human PD-L1 at 1:1000 dilution (GeneTex, Irvine, CA, Cat# GTX104763, RRID: AB\_1240586) and a goat anti-COX-2 antibody at 1:500 dilution (Cayman Chemical, Ann Arbor, Michigan, Cat# 100034, RRID: AB\_10078977). Monoclonal anti-GAPDH antibody (1:50,000 dilution, Sigma-Aldrich, Cat# G8795, RRID: AB\_1078991) was used as loading control. Proteins were visualized with HRP (horseradish peroxidase)-conjugated secondary antibodies using the SuperSignal West Pico Chemiluminescent substrate kit (Thermo Scientific).

## Prostaglandin E2 (PGE<sub>2</sub>) concentration

PGE<sub>2</sub> concentrations were measured as previously described (35) using the supernatant of cells under the different treatment conditions. PGE<sub>2</sub> enzyme immunoassay (EIA) Kit-Monoclonal was used as described by the manufacturer (Cayman Chemical, Ann Arbor, MI).

## Flow cytometry analysis of PD-L1

Approximately  $10^6$  cells were transfected with siRNA for 48h. The following antibodies were used for flow cytometry: APC mouse anti-human PD-L1 (CD274; clone MIH1 from BD Pharmingen, San Diego, CA, USA), and APC Mouse IgG1 Isotype (Clone MOPC-21, BD Pharmingen). Briefly, cells were washed and harvested using PBS EDTA 5 mM buffer. Approximately  $0.5 \times 10^6$  cells were suspended in PBA buffer (PBS containing 0.5% bovine serum albumin and 0.02% sodium azide). Cells were incubated with either PD-L1 or IgG1 antibody in the dark at 4°C for 1h and washed several times in PBA. Flow analyses were performed using a FACS Calibur system (Becton Dickinson Immunocytometry Systems, San Jose, CA,

USA). IgG1 controls were analyzed to delineate the negative population, and to designate the quadrants. The percentage of positive events and the mean fluorescent intensity was measured using Cell Quest software (Becton Dickinson Immunocytometry Systems).

### **Dual-phase extraction and high-resolution $^1\text{H}$ MRS**

Approximately  $2 \times 10^7$  cells were incubated with different siRNA for 48h. Water-soluble and lipid fractions were extracted from the cells using a dual-phase extraction method (36). Briefly, pelleted cells were washed with ice-cold saline, then mixed with 4 mL of ice-cold methanol and vigorously vortexed. After keeping samples on ice for 15 minutes, 4 mL of chloroform were added, vortexed vigorously and kept on ice for an additional 10 minutes. Finally, 4 mL of water were added and the samples were vortexed again. All procedures were performed on ice and samples were stored at  $4^\circ\text{C}$  overnight for phase separation and then centrifuged at  $15,000 \times g$  at  $4^\circ\text{C}$  for 30 minutes. The aqueous phase containing water-soluble metabolites was collected (37). Methanol in the aqueous phase was first evaporated under nitrogen gas, and any water remaining in the aqueous phase was lyophilized. Dried aqueous phase extracts were re-suspended in 0.6 mL deuterated water ( $\text{D}_2\text{O}$ ) for MRS analysis. 3-(trimethylsilyl) propionic 2,2,3,3-d<sub>4</sub> acid sodium salt (TSP) dissolved in  $\text{D}_2\text{O}$  was used as an internal standard. Lipid phase extracts were dried under nitrogen gas stream and re-suspended in 0.6 mL deuterated chloroform and methanol in a 2:1 ratio containing tetramethylsilane (TMS) 0.05% v/v.

High-resolution  $^1\text{H}$  MR spectra were recorded on a Bruker Biospin Avance-III 750 MHz NMR (Bruker Biospin Billerica, MA, USA) spectrometer operating at a proton frequency of 750.21 MHz using a 5-mm broad band inverse (BBI) probe equipped with z-gradient accessories. For quantitative analysis of metabolites, integrals of resonances were determined and normalized to the number of cells and compared to the TSP standard (aqueous phase) or TMS standard (lipid phase) to obtain relative concentrations. Spectra were analyzed using MNova software (Mestrelab Research, Santiago de Compostela, Spain).

### **Clinical data collection**

Molecular data from the TCGA TARGET GTEx database were retrieved from The UCSC Genome Browser database (RRID:SCR\_005780, <https://doi.org/10.1101/326470>) (38). Data were filtered selecting only samples from primary, treatment naïve, tumors. The downloaded data included primary disease and gene expression (for Chk-a and PD-L1). No re-processing or re-normalization was performed on the data. The mean expression, standard deviation and standard error of the mean were calculated for each tumor type. To investigate the correlation between the expression levels of Chk-a and PD-L1, we used the cBioPortal for cancer genomics (RRID:SCR\_014555, <https://www.cbioportal.org/>) (39), using the messenger RNA (mRNA) Expression Z-scores (RNA Seq V2 RSEM) with a z-score threshold  $\pm 2.0$ .

### **Statistical analysis and reproducibility**

Statistical analyses were performed using GraphPad Prism 4 software (GraphPad Software, Inc., San Diego, CA, USA, RRID:SCR\_002798). To determine the statistical significance of the quantified data, an unpaired two-tailed Student's T-test was performed. P values  $\leq 0.05$  were considered significant unless otherwise stated. To calculate the correlation between variables, the Agostino & Pearson normality test with an alpha value of 0.05 was used to test the normality of the data. If the data were normal, the Pearson correlation was used as previously described. If the data were not normal, the nonparametric Spearman correlation coefficient was used. All the statistical analyses were performed using two tailed tests.

## Results

### Chk-a and PD-L1 expression are interactively related

To identify the interactive relationship between Chk-a and PD-L1, we used siRNA to downregulate Chk-a and PD-L1 in TNBC MDA-MB-231 and SUM-149 cells, and in Pa09C and Pa20C human PDAC cells (32). Untreated cells and cells treated with scrambled or luciferase siRNA were used as controls. We used a previously validated siRNA sequence (40) to downregulate Chk-a, and two separate siRNA sequences, labeled PD-L1 #1 and PD-L1 #2, to downregulate PD-L1. Changes in mRNA levels of Chk-a and PD-L1 in siRNA treated cells, compared to untreated cells, are shown in Figure 1. A significant reduction of Chk-a and PD-L1 mRNA levels was detected following treatment with the target-specific siRNAs, given singly or combined, in the two TNBC cell lines (Fig. 1A,B) and in Pa09C cells (Fig. 1C). In Pa20C cells, downregulation of Chk-a was less pronounced (<50%) and there was no decrease in PD-L1 mRNA levels with PD-L1 siRNA treatment (Fig. 1D). Importantly, we found an inverse correlation between Chk-a and PD-L1 mRNA levels. Following Chk-a downregulation, PD-L1 increased by  $85 \pm 11\%$  in MDA-MB-231, by  $80 \pm 15\%$  in SUM-149, and by  $70 \pm 10\%$  in Pa09C cells (values expressed as the mean  $\pm$  standard error of the mean).

Conversely, in MDA-MB-231 and SUM-149 cells, a significant increase in Chk-a expression of more than 50% was observed following PD-L1 downregulation (Fig. 1A, B). In the PDAC cells, only Pa09C cells showed a small but significant increase in Chk-a mRNA expression with PD-L1 downregulation (Fig. 1C). Since PD-L1 was not downregulated in Pa20C cells, we did not detect an increase of Chk-a mRNA in these cells. This inverse dependence was lost when cells were treated with a combination of Chk-a and PD-L1 siRNA. To ensure that the loss of inverse dependence was not due to the lower siRNA concentration, we treated MDA-MB-231 cells with 50 nM Chk-a or PD-L1 #1 siRNA alone and observed similar changes as cells treated with 100 nM siRNA (data not shown). To further establish this inverse relationship, we analyzed the correlation between Chk-a and PD-L1 mRNA expression levels in all four cell lines treated with single siRNA (Supplementary Fig. 1). We found a strong inverse correlation in MDA-MB-231 ( $P < 0.0001$ ,  $r = -0.763$ ) and SUM-149 ( $P < 0.0001$ ,  $r = -0.738$ ) TNBC cells. Pa09C PDAC cells also showed a significant inverse correlation, although weaker than that observed in the TNBC cell lines ( $P = 0.001$ ,  $r = -0.676$ ). Taken together, these data clearly identified an interdependence between Chk-a and PD-L1 at

the genomic level. This interdependence was not observed when both genes were downregulated by siRNA.

### **Changes in Chk-a and PD-L1 mRNA levels are reflected in protein changes**

To determine whether changes in mRNA translated to changes in protein expression, protein levels of Chk-a and PD-L1 were measured in MDA-MB-231 cells by immunoblotting. As shown in Figure 2A, proteins were harvested at 24h, 48h and 72 h post transfection with Chk-a and PD-L1 siRNA either alone or in combination. Chk-a and PD-L1 siRNA treatment resulted in an effective decrease of the targeted proteins when used alone or in combination. Immunoblots showed increased PD-L1 levels at 72h following Chk-a siRNA treatment, in good agreement with previous studies that reported a delayed increase in PD-L1 protein levels compared with mRNA levels (41). Chk-a increased at 24h following PD-L1 siRNA treatment. This Chk-a/PD-L1 interdependence was not observed when cells were treated with both Chk-a and PD-L1 siRNA. Overall, the protein expression patterns were similar to the mRNA patterns.

To evaluate whether changes in PD-L1 mRNA and protein levels resulted in changes at the cell surface, we performed flow cytometry analysis of siRNA treated MDA-MB-231 cells (Fig. 2B and 2C and Supplementary Fig. 2). Treatment with PD-L1 #1 siRNA, either alone or in combination, was effective in reducing both the percentage of PD-L1 positive cells (Fig. 2B) and the Mean Fluorescence Intensity (MFI, Fig. 2C), which reflects the total amount of PD-L1 on the cell surface. Treatment with Chk-a siRNA resulted in a small, but statistically significant increase in the percentage of PD-L1 positive cells when compared to cells treated with either scrambled or luciferase siRNA. This was also observed in MFI data when comparing Chk-a siRNA treated cells with untreated or scrambled siRNA treated cells.

Taken together, these results confirmed that changes in mRNA resulted in changes in PD-L1 protein expression, and its localization on the cell surface. The magnitude of changes in PD-L1 cell surface expression was lower than anticipated based on the changes in mRNA and total level of proteins. This is likely due to the already high cell surface expression of PD-L1 in MDA-MB-231 cells, as reflected by the 99% of PD-L1 positive cells found in untreated cells, making any increase difficult to detect. However, a small but statistically significant increase was observed in the total amount of PD-L1 on the surface, as detected by MFI, in cells treated with Chk-a siRNA.

### **Consequences of Chk-a and PD-L1 downregulation on metabolites**

To assess whether changes in Chk-a or PD-L1 with siRNA treatment altered metabolites including choline containing compounds, we used high resolution <sup>1</sup>H MRS to analyze the aqueous and lipid phases of MDA-MB-231 cell extracts. Significant differences in several metabolites were observed in MDA-MB-231 cells treated with PD-L1 or Chk-a siRNA individually, as shown in the representative aqueous phase spectra in Figure 3A and the data summarized in Figure 3B and Supplementary Table 1. These metabolic changes were mostly eliminated when both targets were downregulated. Data from untreated and luciferase siRNA treated cells were combined into a single control group for clearer presentation, since the metabolic profiles from these cells were comparable. With PD-L1 downregulation, a significant increase

of PC was observed, consistent with the increase of Chk-a mRNA and protein found with PD-L1 downregulation. PD-L1 downregulation also resulted in a significant increase of glutamate, arginine, lactate, creatine, glutathione (GSH), oxidized glutathione (GSSG), and ATP. Treatment with Chk-a siRNA resulted in a significant decrease of PC demonstrating the functional effects of Chk-a downregulation that were in good agreement with previous results (42). Chk-a downregulation resulted in a decrease of acetate, and a significant increase of glutamine, glutamate, aspartate, arginine, pyruvate, lactate, glycerophosphocholine (GPC), creatine, myo-inositol, taurine, GSH, GSSG, NADP, ATP, adenosine and S-methyl-5'-thioadenosine (MTA). Finally, when both Chk-a and PD-L1 were downregulated together, most of these metabolic changes were not observed with the exception of changes in GSH and myo-inositol.

### **Consequences of Chk-a and PD-L1 downregulation on lipids**

High resolution  $^1\text{H}$  MRS of the lipid phase of MDA-MB-231 cell extracts detected significant changes in MRS detectable lipids following Chk-a or PD-L1 downregulation. Representative lipid phase spectra are shown in Figure 4A with the changes in the lipid profile summarized in Figure 4B and Supplementary Table 2. Untreated and luciferase siRNA treated cells were combined into a single control group. Chk-a downregulation resulted in a significant decrease of the total lipid content, as represented by the methyl signal of fatty acids ( $-\text{CH}_3$ ) and the methylene groups at the b position of the carboxylic function ( $\text{OOC}-\text{CH}_2-\text{CH}_2$ ). We also detected significantly decreased levels of arachidonic acid (AA) and eicosapentaenoic acid (EPA), docosahexaenoic acid and linoleic acid. PD-L1 downregulation, consistent with the resultant increase of Chk-a, increased PtdCho, phosphatidylethanolamine (PtdEA), and the total level of lipids, as represented by the methylene groups at the a position of the carboxylic function ( $\text{OOC}-\text{CH}_2$ ). PD-L1 downregulation also caused an increase in the total level of unsaturated lipids, as represented by the fatty acid double bond signal ( $\text{CH}=\text{CH}$ ), the methylene groups at the a position of a double bond ( $\text{CH}=\text{CH}-\text{CH}_2$ ) and diallylic methylene protons ( $\text{CH}=\text{CH}-\text{CH}_2-\text{CH}=\text{CH}$ )<sub>n</sub>. We also detected significant increases in linoleic acid, glycerol, sphingomyelin, and docosahexaenoic acid. Changes in lipids induced with PD-L1 downregulation were mainly eliminated when both Chk-a and PD-L1 were downregulated, with the exception of sphingomyelin, linoleic acid and unsaturated lipids as represented by  $\text{CH}=\text{CH}$ , and  $\text{CH}=\text{CH}-\text{CH}_2$ , suggesting that these changes were mediated through Chk-a.

### **Inflammation and the Chk-a/PD-L1 interdependence**

To further understand the mechanisms underlying the Chk-a/PD-L1 interdependence, we evaluated the role of inflammation, COX-2, in this relationship. COX-2 and its metabolite prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) play roles in inflammation, cancer development and adaptation to changing microenvironments (43). More recently, COX-2 and PGE<sub>2</sub> have been implicated in cancer immunosuppression (44), and COX-2 and PD-L1 expressions were found to be correlated in melanomas (45) and lung adenocarcinomas (46). Chk-a downregulation increased COX-2 mRNA expression by approximately 4-fold in MDA-MB-231 cells compared to untreated cells, but not compared to cells treated with scrambled siRNA (Fig. 5A). On the other hand, PD-L1 downregulation resulted in an over 40-fold increase of COX-2 mRNA, alone or in combination with Chk-a downregulation. Consistent with the relatively small increase of COX-2 with Chk-

a downregulation, COX-2 protein levels (Fig. 5B), and PGE<sub>2</sub> concentrations (Fig. 5C) did not increase with Chk-a siRNA treatment, whereas the 40-fold increase of COX-2 mRNA following treatment with PD-L1 siRNA resulted in an increase of COX-2 protein and PGE<sub>2</sub> concentrations in the cell culture media. To further understand the role of COX-2 in the PD-L1/Chk-a dependence, we performed Chk-a and PD-L1 downregulation studies in MDA-MB-231 cells with COX-2 silenced using COX-2 short hairpin (sh)RNA (shCOX2-MDA-MB-231). We found that although Chk-a and PD-L1 siRNA downregulated the target genes, the increase of PD-L1 with Chk-a downregulation, and the increase of Chk-a with PD-L1 downregulation was eliminated in cells with COX-2 silenced, at the mRNA (Fig. 5D) and protein levels (Fig. 5E). These data indicate that COX-2 is required for the PD-L1 and Chk-a interdependence.

TGF- $\beta$ , an inducer of COX-2 (47), has been directly associated with suppression of the host antitumor immune response (48) and resistance to immune therapies by increasing tumor cell plasticity (49). We therefore analyzed changes in TGF- $\beta$  expression in response to Chk-a and PD-L1 downregulation. As shown in Figure 6, Chk-a downregulation significantly decreased TGF- $\beta$  mRNA expression in TNBC MDA-MB-231, shCOX-2-MDA-MB-231, and SUM-149 cells. In PDAC cells, Pa09C showed a less pronounced decrease in TGF- $\beta$ , while Pa20C showed the smallest decrease. These alterations matched the range of changes in the increase of PD-L1 observed with Chk-a downregulation, where TNBC cells showed the largest increase of PD-L1, followed by Pa09C cells, and Pa20C cells showed no increase. Conversely, downregulating PD-L1 resulted in an increase of TGF- $\beta$  levels, that was most pronounced in TNBC, lesser in Pa09C cells, and none in Pa20C cells, matching the levels of PD-L1 downregulation and the corresponding increase of Chk-a. The increase of TGF- $\beta$  in shCOX-2-MDA-MB-231 cells treated with PD-L1 siRNA was clearly attenuated compared to wild type cells. When both Chk-a and PD-L1 were downregulated, no consistent pattern was observed.

### **Chk-a and PD-L1 interdependence confirmed in human cancers**

To independently confirm the inverse correlation between Chk-a and PD-L1 in human cancers, we analyzed the relationship between the tumoral expression of Chk-a and PD-L1 in TCGA. We calculated mean Chk-a and PD-L1 expression in primary tumor samples from 31 different cancer types (Supplementary Table 3), comprising of more than 9,000 samples. We found an inverse linear correlation between PD-L1 and Chk-a mRNA levels (Fig. 7,  $P=0.001$ ,  $r=-0.562$ ). When we analyzed individual tumor values, irrespective of the tumor type (Supplementary Fig. 3), we also found a significant inverse correlation ( $P<0.001$ ,  $r=-0.358$ ). When we examined this relationship within individual tumor types, we found a statistically significant inverse correlation ( $p<0.001$ ) for 21 out of the 31 tumor types analyzed (supplementary Table 4). When categorizing receptor status in the breast cancer group, we found that TNBC showed the most significant inverse correlation ( $P=0.003$ ,  $r=-0.31$ ), whereas the correlation was weaker or not statistically significant in the other breast cancers.

We further analyzed the TCGA samples by ranging primary tumors according to the mRNA levels of Chk-a and PD-L1 independently of the tumor type. Tumors with 10% lowest mRNA levels for Chk-a had significantly higher levels of PD-L1 (Supplementary Fig. 4A) compared with tumors with 10% highest

mRNA levels for Chk-a. Similarly, tumors with 10% lowest mRNA levels for PD-L1 had significantly higher levels of Chk-a (Supplementary Fig. 4B) compared with tumors with 10% highest mRNA levels for PD-L1. These results are in good agreement with our experimental data showing an increase in PD-L1 with Chk-a downregulation and an increase in Chk-a with PD-L1 downregulation, further confirming this relationship in human cancers.

## Discussion

Our data identified previously unknown roles of the immune checkpoint PD-L1 in cancer cell metabolic reprogramming that are summarized in the schematic in Figure 8. These data suggest that many of the metabolic changes are mediated through Chk-a, COX-2 and TGF- $\beta$ . We found that PD-L1 expression significantly increased following downregulation of Chk-a, an enzyme that is overexpressed in most cancer cells. Conversely, downregulation of PD-L1 significantly increased expression of Chk-a. This inverse dependence was eliminated when both genes were downregulated. Similarly, the metabolic changes detected with individual downregulation of Chk-a or PD-L1 were significantly attenuated when both genes were downregulated, identifying the interaction between these two molecules as necessary for many of the metabolic changes. The interaction between the two molecules was also eliminated in COX-2 silenced cells. TGF- $\beta$  significantly decreased with Chk-a downregulation, significantly increased with PD-L1 downregulation, and remained unchanged when both Chk-a and PD-L1 were downregulated, identifying COX-2 and TGF- $\beta$  as playing a role in this interactive relationship. The interaction between PD-L1 and Chk-a was observed in both breast cancer cell lines. However, one of the two PDAC cell lines, Pa20C, did not display this interactive relationship. Although one reason for the difference between the two PDAC cell lines may be that we were unable to achieve sufficient downregulation of Chk-a or PD-L1 in Pa20C cells to the levels achieved in Pa09C cells, the implications of these data on immune surveillance in different pancreatic cancer subtypes should also be considered. While the use of human cancer cells in immune suppressed mice precludes evaluating changes in tumor immune cells in these xenograft models, techniques such as mass spectrometry imaging that allow overlay of metabolomic information with immunohistochemical analysis of immune cells in human cancer tissue may expand our understanding of the role of metabolism and the relationship between Chk-a and PD-L1 in immune surveillance.

Both Chk-a (17, 19, 50-53) and PD-L1 (54-59) play pro-oncogenic roles beyond their traditional functions in PC biosynthesis and in immunomodulation, respectively. Here, for the first time, we identified the direct involvement of Chk-a in immunosuppression, as Chk-a downregulation significantly increased PD-L1 levels. Chk-a downregulation also shifted cancer cells towards a more immunosuppressive profile through metabolic reprogramming, increasing the production of metabolites such as lactate (12), glutamate (14), MTA (60) or glutamine (61), that have been linked to increased immune resistance of cancer cells. In a recent study, lower lactate production by cancer cells led to lower *in vivo* extracellular lactate and improved functioning of T-cells (62). Secretion of glutamate (63) and an excess of extracellular glutamate in the TME led to T-cell dysfunction (64). The increase of PD-L1 as a consequence of Chk-a downregulation, identified low Chk-a as contributing to immune suppression in

cancer cells, different from its role as an oncogenic protein when overexpressed. Consequently treatments that target Chk-a (27) may result in cancer cells escaping immune surveillance.

Downregulation of PD-L1 also resulted in a significant increase of immune suppressive metabolites such as lactate (8, 62, 65), glutamate (14, 64), and PC (66), although the number of metabolites that were altered were fewer compared to Chk-a downregulation. The significant increase of lipid production and changes in the lipid profile following PD-L1 downregulation may also contribute to cancer cells escaping immune surveillance. Several studies have shown that lipids can reprogram tumor infiltrating myeloid and T cells towards immunosuppressive and anti-inflammatory phenotypes(67-70). The metabolic reprogramming observed following downregulation of PD-L1 and its effects on the TIME merit further investigation. This metabolic reprogramming that, based on our data, is mediated through Chk-a, may assist cancer cells in escaping immune surveillance in response to a decrease of PD-L1, or may be a component of the PD-L1 immune checkpoint program in activating the immune system. Further studies investigating metabolic reprogramming controlled by the different immune checkpoints will provide a more comprehensive understanding of the interaction between the immune checkpoints and metabolism.

PD-L1 downregulation may also create a more immunosuppressive profile through increased expression of TGF- $\beta$  and COX-2, both of which are related to immune escape (71) and anti-PD-L1 treatment failure (72). We detected increased TGF- $\beta$ , COX-2 and lipid production with PD-L1 downregulation. Conversely, TGF- $\beta$  and lipid production decreased following increased PD-L1 expression in response to Chk-a downregulation. When both Chk-a and PD-L1 were downregulated, or when COX-2 was silenced, these changes were eliminated. Our data support an active role of both TGF- $\beta$  and COX-2 in the dependence between Chk-a and PD-L1. Although not investigated here, the roles of the inflammatory transcription factor NF- $\kappa$ -B and HIF regulation in mediating the interactions between Chk-a and PD-L1 should be investigated in future studies.

COX-2 inhibition downregulated PD-L1 levels in Lewis lung carcinoma and CMT167 models (73) and in human melanoma cells (45). On the other hand, COX-2 inhibition did not impact PD-L1 levels of lung cancer cells (46), or only affected tumor-associated macrophages and myeloid-derived suppressor cells (41), or decreased PD-L1 by a COX-2/PGE<sub>2</sub> independent pathway in breast cancer cells (74). Our data are consistent with previous observations of TGF- $\beta$  inversely correlating with PD-L1 expression in neuroblastoma cells (75). Furthermore, several preclinical studies have shown that targeting the TGF- $\beta$  signaling pathway synergizes with PD-L1 blocking, improving tumor control and enhancing anti-tumor immunity (72, 76). Clinically, it is well established that different tumor types use TGF- $\beta$  production to evade immune attack (71), and the overexpression of TGF- $\beta$  and PGE<sub>2</sub> diminished tumor recognition by T cells (77). Our results demonstrate, for the first time, that PD-L1 plays a significant role in COX-2 and TGF- $\beta$  modulation in cancer cells.

A major unmet need in treatment with immune checkpoint inhibitors is the lack of a noninvasive technique to identify patients who may benefit from such a therapy (78). Our results suggest that tumors

with low PD-L1 expression may have high Chk-a expression and consequently high PC and total choline that can be detected noninvasively with  $^1\text{H}$  MRS. Future studies relating total choline detected by  $^1\text{H}$  MRS in tumors to PD-L1 expression in biopsy samples may provide further evidence for the development of the total choline signal as a biomarker to predict for PD-L1 expression levels (16, 24).

## Conclusions

Although the role of immune checkpoints in immune cell metabolism has been widely studied (6), few data are available on the regulation of cancer cell metabolism by immune checkpoints. Immune checkpoint overexpression has been linked to increased glycolysis and lactate production in breast cancer cells both *in vitro* and *in vivo* (79). Targeting protein B7-H3 (CD276) in cancer cells at the genomic level (79) or PD-L1 with antibodies in a sarcoma model (56), resulted in decreased glycolysis and glucose consumption both *in vitro* and *in vivo*. We identified for the first time, a dual role for PD-L1, as being modulated by and being a modulator of tumor metabolism. Similarly, we identified for the first time the role of Chk-a in immunosuppression. This is especially relevant as this gene is commonly overexpressed in most cancers (16). These observations may provide new insights in the rational design of combinatorial therapies targeting immune checkpoint inhibitors and cancer metabolism.

## List Of Abbreviations

AA: arachidonic acid

Chk- $\alpha$ : choline kinase-  $\alpha$

Cho: choline

COX-2: Prostaglandin-endoperoxide synthase 2

EPA: eicosapentaenoic acid

GSH: glutathione

GSSG: oxidized glutathione

GPC: glycerophosphocholine

HPRT1: hypoxanthine phosphoribosyltransferase 1

MFI: Mean Fluorescence Intensity

mRNA: messenger RNA

MRS: magnetic resonance spectroscopy

MTA: S-methyl-5'-thioadenosine

PD-1: programmed cell death protein-1

PD-L1: programmed death-ligand 1

PDAC: human pancreatic ductal adenocarcinoma

TCGA: The Cancer Genome Atlas Program

TIME: tumor immune microenvironment

TME: tumor microenvironment

TNBC: human triple negative breast cancer

PC: phosphocholine

PGE<sub>2</sub>: Prostaglandin E2

PtdCho: phosphatidylcholine

PtdEA: phosphatidylethanolamine

rt-PCR: real-time polymerase chain reaction

shRNA: short hairpin RNA

siRNA: small interfering RNA

STR: short tandem repeat

TGF- $\beta$ : transforming growth factor beta

TMS: tetramethylsilane

TSP: 3-(trimethylsilyl) propionic 2,2,3,3-d<sub>4</sub> acid sodium salt

## **Declarations**

### **Ethics approval and consent to participate**

Not applicable

### **Consent for publication**

Not applicable

## Availability of data and materials

**Lead Contact:** Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Zaver M Bhujwalla (zbhujwa1@jhmi.edu).

**Data Availability:** The accession number for the raw spectra data reported in this paper is DOI: 10.17632/r4z94fxtwx.1. Data are uploaded into Mendeley Data. The published article (in supplementary information) includes all TCGA data analyzed during this study (Supplementary Tables 3 and 4).

## Competing interests

The authors declare that they have no competing interests.

## Funding

This work was supported by NIH R35 CA209960, R01 CA82337, P41 EB024495 and P30 CA006973. J.P.T. was supported by Fundación Martín-Escudero and Marie Skłodowska-Curie Individual Fellowships.

## Authors' contributions

Conceptualization, J.P.T. and Z.M.B.; Methodology, J.P.T., M.F.P., B.K. and Z.M.B.; Investigation, J.P.T., M.F.P., Y.M., and B.K.; Writing – Original Draft, J.P.T.; Writing – Review & Editing, J.P.T., M.F.P., B.K. and Z.M.B.; Funding Acquisition, J.P.T. and Z.M.B.; Resources, B.K. and Y.M.; Supervision, Z.M.B.

## Acknowledgements

Not applicable

## References

1. Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. *Curr Opin Immunol.* 2007;19(3):309-14.
2. Renner K, Singer K, Koehl GE, Geissler EK, Peter K, Siska PJ, et al. Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment. *Frontiers in immunology.* 2017;8:248-.
3. Cassim S, Pouyssegur J. Tumor Microenvironment: A Metabolic Player that Shapes the Immune Response. *International journal of molecular sciences.* 2019;21(1):157.
4. Wang M, Zhang C, Song Y, Wang Z, Wang Y, Luo F, et al. Mechanism of immune evasion in breast cancer. *Onco Targets Ther.* 2017;10:1561-73.
5. Dougan SK. The Pancreatic Cancer Microenvironment. *Cancer J.* 2017;23(6):321-5.
6. Li X, Wenes M, Romero P, Huang SC, Fendt SM, Ho PC. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. *Nat Rev Clin Oncol.* 2019.

7. Kouidhi S, Ben Ayed F, Benammar Elgaaied A. Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy. *Front Immunol.* 2018;9:353.
8. Husain Z, Huang Y, Seth P, Sukhatme VP. Tumor-Derived Lactate Modifies Antitumor Immune Response: Effect on Myeloid-Derived Suppressor Cells and NK Cells. *The Journal of Immunology.* 2013;191(3):1486-95.
9. Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, et al. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. *Cell Metab.* 2018;27(5):977-87 e4.
10. Hu YM, Hsiung YC, Pai MH, Yeh SL. Glutamine Administration in Early or Late Septic Phase Downregulates Lymphocyte PD-1/PD-L1 Expression and the Inflammatory Response in Mice With Polymicrobial Sepsis. *JPEN Journal of parenteral and enteral nutrition.* 2018;42(3):538-49.
11. Roux C, Jafari SM, Shinde R, Duncan G, Cescon DW, Silvester J, et al. Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1. *Proceedings of the National Academy of Sciences.* 2019;116(10):4326-35.
12. Feng J, Yang H, Zhang Y, Wei H, Zhu Z, Zhu B, et al. Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells. *Oncogene.* 2017;36(42):5829-39.
13. Brin E, Wu K, Lu HT, He Y, Dai Z, He W. PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration. *Oncotarget.* 2017;8(35):58948-63.
14. Xia X, Zhou W, Guo C, Fu Z, Zhu L, Li P, et al. Glutaminolysis Mediated by MALT1 Protease Activity Facilitates PD-L1 Expression on ABC-DLBCL Cells and Contributes to Their Immune Evasion. *Front Oncol.* 2018;8:632.
15. Wang L, Yang X, Li D, Liang Z, Chen Y, Ma G, et al. The elevated glutaminolysis of bladder cancer and T cells in a simulated tumor microenvironment contributes to the up-regulation of PD-L1 expression by interferon-gamma. *Onco Targets Ther.* 2018;11:7229-43.
16. Glunde K, Penet MF, Jiang L, Jacobs MA, Bhujwala ZM. Choline metabolism-based molecular diagnosis of cancer: an update. *Expert Rev Mol Diagn.* 2015;15(6):735-47.
17. Xiong J, Bian J, Wang L, Zhou JY, Wang Y, Zhao Y, et al. Dysregulated choline metabolism in T-cell lymphoma: role of choline kinase-alpha and therapeutic targeting. *Blood Cancer J.* 2015;5:287.
18. Glunde K, Raman V, Mori N, Bhujwala ZM. RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. *Cancer Res.* 2005;65(23):11034-43.
19. Mariotto E, Viola G, Ronca R, Persano L, Aveic S, Bhujwala ZM, et al. Choline Kinase Alpha Inhibition by EB-3D Triggers Cellular Senescence, Reduces Tumor Growth and Metastatic Dissemination in Breast Cancer. *Cancers (Basel).* 2018;10(10).
20. Yeagle PL. Chapter 3 - Biogenesis of Membrane Lipids. In: Yeagle PL, editor. *The Membranes of Cells (Third Edition)*. Boston: Academic Press; 2016. p. 57-71.

21. Ramirez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, Taron M, Ramirez de Molina V, Cejas P, et al. Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. *Lancet Oncol.* 2007;8(10):889-97.
22. Kwee SA, Hernandez B, Chan O, Wong L. Choline kinase alpha and hexokinase-2 protein expression in hepatocellular carcinoma: association with survival. *PLoS One.* 2012;7(10):e46591.
23. Challapalli A, Trousil S, Hazell S, Kozlowski K, Gudi M, Aboagye EO, et al. Exploiting altered patterns of choline kinase-alpha expression on human prostate tissue to prognosticate prostate cancer. *J Clin Pathol.* 2015;68(9):703-9.
24. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. *Nat Rev Cancer.* 2011;11(12):835-48.
25. Zech SG, Kohlmann A, Zhou T, Li F, Squillace RM, Parillon LE, et al. Novel Small Molecule Inhibitors of Choline Kinase Identified by Fragment-Based Drug Discovery. *J Med Chem.* 2016;59(2):671-86.
26. Trousil S, Kaliszczak M, Schug Z, Nguyen QD, Tomasi G, Favicchio R, et al. The novel choline kinase inhibitor ICL-CCIC-0019 reprograms cellular metabolism and inhibits cancer cell growth. *Oncotarget.* 2016;7(24):37103-20.
27. Kall SL, Delikatny EJ, Lavie A. Identification of a Unique Inhibitor-Binding Site on Choline Kinase alpha. *Biochemistry.* 2018;57(8):1316-25.
28. Gravbrot N, Gilbert-Gard K, Mehta P, Ghotmi Y, Banerjee M, Mazis C, et al. Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. *Antibodies (Basel).* 2019;8(4):51.
29. Wróbel S, Przybyło M, Stępień E. The Clinical Trial Landscape for Melanoma Therapies. *J Clin Med.* 2019;8(3):368.
30. Aroldi F, Zaniboni A. Immunotherapy for pancreatic cancer: present and future. *Immunotherapy.* 2017;9(7):607-16.
31. Stasinopoulos I, O'Brien DR, Wildes F, Glunde K, Bhujwalla ZM. Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells. *Molecular cancer research : MCR.* 2007;5(5):435-42.
32. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science.* 2008;321(5897):1801-6.
33. Bairoch A. The Cellosaurus, a Cell-Line Knowledge Resource. *Journal of biomolecular techniques : JBT.* 2018;29(2):25-38.
34. Penet MF, Chen Z, Mori N, Krishnamachary B, Bhujwalla ZM. Magnetic Resonance Spectroscopy of siRNA-Based Cancer Therapy. *Methods Mol Biol.* 2016;1372:37-47.
35. Krishnamachary B, Stasinopoulos I, Kakkad S, Penet MF, Jacob D, Wildes F, et al. Breast cancer cell cyclooxygenase-2 expression alters extracellular matrix structure and function and numbers of cancer associated fibroblasts. *Oncotarget.* 2017;8(11):17981-94.

36. Bharti SK, Mironchik Y, Wildes F, Penet MF, Goggins E, Krishnamachary B, et al. Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. *Oncotarget*. 2018;9(20):15326-39.
37. Tkac I, Starcuk Z, Choi IY, Gruetter R. In vivo <sup>1</sup>H NMR spectroscopy of rat brain at 1 ms echo time. *Magn Reson Med*. 1999;41(4):649-56.
38. Haeussler M, Zweig AS, Tyner C, Speir ML, Rosenbloom KR, Raney BJ, et al. The UCSC Genome Browser database: 2019 update. *Nucleic Acids Res*. 2019;47(D1):D853-D8.
39. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Science signaling*. 2013;6(269):pl1.
40. Chen Z, Krishnamachary B, Bhujwalla ZM. Degradable Dextran Nanopolymer as a Carrier for Choline Kinase (ChoK) siRNA Cancer Therapy. *Nanomaterials (Basel)*. 2016;6(2).
41. Prima V, Kaliberova LN, Kaliberov S, Curiel DT, Kusmartsev S. COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. *Proc Natl Acad Sci U S A*. 2017;114(5):1117-22.
42. Mori N, Glunde K, Takagi T, Raman V, Bhujwalla ZM. Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. *Cancer Res*. 2007;67(23):11284-90.
43. Stasinopoulos I, Shah T, Penet MF, Krishnamachary B, Bhujwalla ZM. COX-2 in cancer: Gordian knot or Achilles heel? *Frontiers in pharmacology*. 2013;4:34.
44. Harris RE, Casto BC, Harris ZM. Cyclooxygenase-2 and the inflammationogenesis of breast cancer. *World journal of clinical oncology*. 2014;5(4):677-92.
45. Botti G, Fratangelo F, Cerrone M, Liguori G, Cantile M, Anniciello AM, et al. COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. *Journal of Translational Medicine*. 2017;15(1):46.
46. Shimizu K, Okita R, Saisho S, Maeda AI, Nojima Y, Nakata M. Impact of COX2 Inhibitor for Regulation of PD-L1 Expression in Non-small Cell Lung Cancer. *Anticancer Res*. 2018;38(8):4637-44.
47. Ding Q, Bai Y-F, Wang Y-Q, An R-H. TGF-beta1 reverses inhibition of COX-2 with NS398 and increases invasion in prostate cancer cells. *Am J Med Sci*. 2010;339(5):425-32.
48. Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. *Nature*. 2018;554(7693):544-8.
49. Lind H, Gameiro SR, Jochems C, Donahue RN, Strauss J, Gulley JLMD, et al. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances. *Journal for immunotherapy of cancer*. 2020;8(1):e000433.
50. Chua BT, Gallego-Ortega D, Ramirez de Molina A, Ullrich A, Lacal JC, Downward J. Regulation of Akt(ser473) phosphorylation by choline kinase in breast carcinoma cells. *Mol Cancer*. 2009;8:131.
51. Clem BF, Clem AL, Yalcin A, Goswami U, Arumugam S, Telang S, et al. A novel small molecule antagonist of choline kinase-alpha that simultaneously suppresses MAPK and PI3K/AKT signaling. *Oncogene*. 2011;30(30):3370-80.

52. Hu L, Wang RY, Cai J, Feng D, Yang GZ, Xu QG, et al. Overexpression of CHKA contributes to tumor progression and metastasis and predicts poor prognosis in colorectal carcinoma. *Oncotarget*. 2016;7(41):66660-78.
53. Mariotto E, Bortolozzi R, Volpin I, Carta D, Serafin V, Accordi B, et al. EB-3D a novel choline kinase inhibitor induces deregulation of the AMPK-mTOR pathway and apoptosis in leukemia T-cells. *Biochem Pharmacol*. 2018;155:213-23.
54. Gupta S, Roy A, Dwarakanath BS. Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy. *Front Oncol*. 2017;7:68.
55. Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, et al. Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. *Cancer Res*. 2016;76(23):6964-74.
56. Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. *Cell*. 2015;162(6):1229-41.
57. Escors D, Gato-Canas M, Zuazo M, Arasanz H, Garcia-Granda MJ, Vera R, et al. The intracellular signalosome of PD-L1 in cancer cells. *Signal Transduct Target Ther*. 2018;3:26.
58. Dong P, Xiong Y, Yue J, Hanley SJB, Watari H. Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion. *Front Oncol*. 2018;8:386.
59. Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, et al. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. *Cell*. 2015;162(6):1242-56.
60. Henrich FC, Singer K, Poller K, Bernhardt L, Strobl CD, Limm K, et al. Suppressive effects of tumor cell-derived 5'-deoxy-5'-methylthioadenosine on human T cells. *Oncoimmunology*. 2016;5(8):e1184802-e.
61. Wang L, Yang X, Li D, Liang Z, Chen Y, Ma G, et al. The elevated glutaminolysis of bladder cancer and T cells in a simulated tumor microenvironment contributes to the up-regulation of PD-L1 expression by interferon- $\gamma$ . *OncoTargets and therapy*. 2018;11:7229-43.
62. Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, et al. LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. *Cell Metab*. 2016;24(5):657-71.
63. Briggs Kimberly J, Koivunen P, Cao S, Backus Keriann M, Olenchock Benjamin A, Patel H, et al. Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine. *Cell*. 2016;166(1):126-39.
64. Singer K, Cheng WC, Kreutz M, Ho PC, Siska PJ. Immunometabolism in cancer at a glance. *Dis Model Mech*. 2018;11(8).
65. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad EK, et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. *Cancer Res*. 2000;60(4):916-21.
66. Lovell TM, Woods RJ, Butlin DJ, Brayley KJ, Manyonda IT, Jarvis J, et al. Identification of a novel mammalian post-translational modification, phosphocholine, on placental secretory polypeptides. *J Mol Endocrinol*. 2007;39(3):189-98.

67. Al-Khami AA, Zheng L, Del Valle L, Hossain F, Wyczechowska D, Zabaleta J, et al. Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells. *Oncoimmunology*. 2017;6(10):e1344804.
68. Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA, et al. Lipid accumulation and dendritic cell dysfunction in cancer. *Nat Med*. 2010;16(8):880-6.
69. Niu Z, Shi Q, Zhang W, Shu Y, Yang N, Chen B, et al. Caspase-1 cleaves PPARgamma for potentiating the pro-tumor action of TAMs. *Nat Commun*. 2017;8(1):766.
70. Muroski ME, Miska J, Chang AL, Zhang P, Rashidi A, Moore H, et al. Fatty Acid Uptake in T Cell Subsets Using a Quantum Dot Fatty Acid Conjugate. *Sci Rep*. 2017;7(1):5790.
71. Huang JJ, Blobel GC. Dichotomous roles of TGF-beta in human cancer. *Biochem Soc Trans*. 2016;44(5):1441-54.
72. Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. *Nature*. 2018;554(7693):544-8.
73. Tang H, Liu Y, Wang C, Zheng H, Chen Y, Liu W, et al. Inhibition of COX-2 and EGFR by Melafolone Improves Anti-PD-1 Therapy through Vascular Normalization and PD-L1 Downregulation in Lung Cancer. *J Pharmacol Exp Ther*. 2019;368(3):401-13.
74. Liang M, Yang H, Fu J. Nimesulide inhibits IFN-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms. *Cancer Lett*. 2009;276(1):47-52.
75. Boes M, Meyer-Wentrup F. TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells. *Cancer Lett*. 2015;361(1):49-56.
76. Ravi R, Noonan KA, Pham V, Bedi R, Zhavoronkov A, Ozerov IV, et al. Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFbeta enhance the efficacy of cancer immunotherapy. *Nat Commun*. 2018;9(1):741.
77. Kumai T, Oikawa K, Aoki N, Kimura S, Harabuchi Y, Celis E, et al. Tumor-derived TGF-beta and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitor. *J Transl Med*. 2014;12:265.
78. Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, et al. (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. *Nat Med*. 2018.
79. Lim S, Liu H, Madeira da Silva L, Arora R, Liu Z, Phillips JB, et al. Immunoregulatory Protein B7-H3 Reprograms Glucose Metabolism in Cancer Cells by ROS-Mediated Stabilization of HIF1alpha. *Cancer Res*. 2016;76(8):2231-42.